Study Shows AstraZeneca

Research said the studi Wholesale Inflatable Arch 1 show that treatment with vandetanib reduc the risk of thyroid cancer progress by 54% compar with patient not receiv the drug. The studi data isn't matur enough to show whether slow diseas progress will translat into an increas in overal survival. AstraZeneca is also conduct anoth trial in a more common form of papillari thyroid cancer.

AstraZeneca withdrew an applic from the U.S. Food and Drug Administr for approv of vandetanib in the lung cancer set after clinic data fail to show it increas patients' surviv time. The compani had propos sell vandetanib under the brand name Zactima. Vandetanib wa previous studi as a treatment for advanc non-smal cell lung cancer in combin with chemotherapy. Last year.

execut director of medic scienc at AstraZeneca,Peter Langmuir. said the compani plan to file for FDA approv of vandetanib to treat medullari thyroid cancer base on the studi results. The result ar schedul to be present later Mondai at the American Societi of Clinic Oncology' annual meeting.

or sham,A straZeneca' studi involv 331 patient with advanc medullari thyroid cancer. About 230 patient receiv vandetanib while 100 receiv a placebo. treatment.

the studi show that 48% of patient receiv vandetanib continu on treatment while 37% of patient progressed,A fter an averag follow-up of 24 months. or had their diseas get worse. Fifteen percent of patient in the studi died.